WallStSmart

Biodesix Inc (BDSX)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 68340% more annual revenue ($65.77B vs $96.10M). MRK leads profitability with a 13.6% profit margin vs -33.3%. MRK earns a higher WallStSmart Score of 50/100 (D+).

BDSX

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 4.0Quality: 4.5
Piotroski: 4/9Altman Z: -7.79

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDSXSignificantly Overvalued (-19.0%)

Margin of Safety

-19.0%

Fair Value

$8.70

Current Price

$17.35

$8.65 premium

UndervaluedFair: $8.70Overvalued
MRKSignificantly Overvalued (-40.6%)

Margin of Safety

-40.6%

Fair Value

$80.96

Current Price

$120.79

$39.83 premium

UndervaluedFair: $80.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDSX1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
42.3%10/10

Revenue surging 42.3% year-over-year

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

BDSX4 concerns · Avg: 3.3/10
Price/BookValuation
19.3x4/10

Trading at 19.3x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$161.55M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-349.9%2/10

ROE of -349.9% — below average capital efficiency

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BDSX

The strongest argument for BDSX centers on Revenue Growth. Revenue growth of 42.3% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : BDSX

The primary concerns for BDSX are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 7.84 is elevated, increasing financial risk.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

BDSX profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.

BDSX carries more volatility with a beta of 0.59 — expect wider price swings.

BDSX is growing revenue faster at 42.3% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Biodesix Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?